The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Blu Pagamentos
Advised Blu Pagamentos, a high-growth Brazilian B2B cash management fintech firm, on the sale of a minority stake
Synfonium / Qwant / Shadow
Advised Banque des Territoires / Groupe Caisse des Dépôts (CDC), a French Public Institution, on the investment in the newly created platform Synfonium, incorporating Shadow, a cloud-based platform, and Qwant, a sovereign search engine. CDC will hold a 25% stake in Synfonium, while Octave Klaba and Miroslaw Klaba, the co-founders of OVHcloud, will hold the remaining 75%
BARTEC Group
Advised Capvis, a leading Swiss private equity firm, on its acquisition of the BARTEC Group, a leading European provider of industrial safety technology, from Allianz Capital Partners, the captive private equity arm of Allianz AG, and the Barlian family (founding family)
Infracommerce
Advised Brazil-based Infracommerce, a leader in designing, building and delivering the digital B2C and B2B go-to-market strategy for large enterprises, on its Series E funding round
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
Verivox Holding Limited
Advised the shareholders of Verivox Holdings Limited, comprising Independent News & Media plc and the founders and joint CEOs of Verivox, on the sale of 51% in Verivox, Germany’s leading price comparison website for energy and telecommunications services, to Oakley Capital Private Equity
MorphoSys AG
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
Deltalab
Advising Deltalab, a leading Spanish laboratory solutions provider with dedicated manufacturing capacity, on the sale of the company to SCG Packaging Public Company Limited, the largest integrated packaging and paper company in Southeast Asia
Sistemas Informaticos Abiertos, S.A.
Advised Indra (BME:IDR), a leading Spanish IT and transport & defense player, on the acquisition of Sistemas Informáticos Abiertos S.A. (“SIA”), the #3 cybersecurity player in Spain
Recepta Biopharma
Advised Recepta Biopharma on a capital raise
Portfolio of 16 European Consumer Healthcare brands from Sanofi
Advising Sanofi, a leading global player in the Consumer Healthcare market, on the divestiture of a portfolio of 16 European Consumer Healthcare brands to STADA, a German pharmaceutical and consumer healthcare company owned by Bain Capital and Cinven
Radiogroup Participações S.A.
Advised Radiogroup, a regional leader in cancer treatment through radiotherapy, on its sale of a majority stake to Grupo Oncoclínicas
Faes Farma, flagship product Bilastine
Advised Faes Farma in the signing of a long-term license agreement for its flagship product Bilastine with Hikma Specialty USA INC, a subsidiary of Hikma Pharmaceuticals PLC, for the United States of America
Locaweb Serviços de Internet S.A.
Advised Locaweb, a pioneer in B2B tech solutions for businesses digital transformation in Brazil with 2 main pillars: BeOnline/SaaS and Commerce
Akorn Pharmaceuticals Portfolio of Branded Ophthalmic Products
Advised Akorn Pharmaceuticals, a specialty pharmaceuticals manufacturer and marketer, on the divestiture of its portfolio of branded ophthalmic products to Laboratoires Théa SAS
VX Fiber
Advised VX Fiber, an international infrastructure and technology business focused on Fibre-to-the-Home networks, on its sale to the infrastructure fund AMP Capital
WEX Inc. - Brazilian Operations/Subsidiary
Advised WEX Inc., a leading fleet and B2B payments company, on the divestiture of its Brazilian subsidiary to Vila Rica Capital.
Cura Imagem e Diagnóstico Ltda.
Advising Cura, a leading independent provider of diagnostic imaging (MRI, CT, etc.) and other clinical analysis services on the sale of 70% of its stake to the PE fund Vinci Partners
Kyowa Kirin International’s established medicines business
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
Policard
Advised Policard, one of the largest electronic payment companies in Brazil, on the combination of its business with the Brazilian operations of Groupe Up, one of the leading employee benefits, public, social and loyalty programs providers in the world
Resource Optimization Software Business Area of Net Insight
Advising Net Insight AB, a global leader in media networks, on the divestment of its resource optimization software business area, doing business as “ScheduALL” to Xytech Systems Corporation
Clinigen Ltd’s Lamda Laboratories
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
Unfors Raysafe AB
Advised the Sixth Swedish National Pension Fund on the sale of Unfors Raysafe AB, a provider of easy-to-use products that help to reduce unnecessary radiation exposure, to Fluke Biomedical Corp., a subsidiary of Danaher Corp. that manufactures biomedical test and simulation products
Cura Imagem e Diagnóstico Ltda.
Advised Cura, a leading independent provider of diagnostic imaging (MRI, CT, etc.) and other clinical analysis services on the sale of 70% of its stake to the PE fund Vinci Partners
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company